Shareholders overwhelmingly approve the creation of a new class of Exchangeable Shares of Canopy Growth, enabling the acceleration of Canopy Growth's entry into the U.S. THC market, which is expected to be approximately $50B in 2026.1Canopy USA expected to advance imminently with triggering acquisition of U.S. assets.SMITHS FALLS, ON, April 15, 2024 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announced the voting results from its special meeting of shareholders held on Friday, April 12, 2024 (the "Meeting").

MONTRÉAL, le 18 avril 2024 /CNW/ - La Compagnie Électrique Lion (NYSE: LEV) (TSX: LEV) (« Lion » ou la « Société »), chef de file dans la fabrication de véhicules urbains de poids moyen et lourd 100 % électriques, a annoncé aujourd'hui une réduction de ses effectifs, laquelle combinée à d'autres mesures de réduction de coûts, vise à rationaliser davantage ses dépenses d'exploitation et à aligner sa structure de coûts à la dynamique actuelle du marché.

Trading Symbol: ELR (TSX); EPS (JSE) VANCOUVER, BC, April 17, 2024 /CNW/ - Eastern Platinum Limited ("Eastplats" or the "Company") is providing this bi-weekly default status report in accordance with National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").  On April 4, 2024, the Company announced that it was unable to file its annual audited financial statements for the fiscal year ended December 31, 2023 and the related management's discussion and analysis and annual information form for the fiscal year ended December 31, 2023 (the "Required Filings") by the deadline of April 1, 2024.

VANCOUVER, BC, April 17, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies,  is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").